The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 17, 2025
Filed:
Feb. 22, 2019
Applicant:
Wuhan Yzy Biopharma Co., Ltd., Wuhan, CN;
Inventors:
Jing Zhang, Wuhan, CN;
Lijuan Fang, Wuhan, CN;
Yongxiang Yan, Wuhan, CN;
Liang Zeng, Wuhan, CN;
Pengfei Zhou, Wuhan, CN;
Assignee:
Wuhan YZY Biopharma Co., Ltd., Wuhan, CN;
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2827 (2013.01); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); C07K 16/3007 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01);
Abstract
The present disclosure relates to a modified Fc fragment, antibodies containing the same and the use thereof. The Fc fragment is derived from human IgG1, and the constant region CH2 domain of the Fc fragment contains multiple substitutions. Such substitution can significantly reduce the binding ability of Fc fragment to Fcγ receptors (FcγR), and reduce the non-specific activation of T cells by antibodies (such as anti-CD3 antibodies).